# US 2013/0280341 A1 · Composition and method to alleviate joint pain

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0280341 A1
- Document ID: US20130280341A1
- Status: Published application
- Kind: A1
- Application number: 13/920,316
- Filed: 2013-06-18
- Published: 2013-10-24
- Earliest claimed: 2009-07-23
- Assignees: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
- Applicants: U.S. NUTRACEUTICALS, LLC d/b/a Valensa International
- Inventors: John A. MINATELLI; W. Stephen Hill; Swati Sebastian Thomas; Lingan Rajendran; Rudi E. Moerck
- Web page: https://patentgrep.com/patent/US20130280341A1

## CPC

- A61K 31/202: having three or more double bonds, e.g. linolenic (eicosanoids, e.g. leukotrienes A61K31/557)
- A61K 31/122: having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
- A61K 31/728: Hyaluronic acid
- A61K 35/612: Crustaceans, e.g. crabs, lobsters, shrimps, krill or crayfish; Barnacles
- A61K 36/05: Chlorophycota or chlorophyta (green algae), e.g. Chlorella
- A61K 36/185: Magnoliopsida (dicotyledons)
- A61K 36/324: Boswellia, e.g. frankincense
- A61K 36/74: Rubiaceae (Madder family)
- A61K 36/9066: Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Beneficial and synergistic effects for alleviating joint pain and symptoms of osteoarthritis and/or rheumatoid arthritis have been found with krill oil and/or marine oil in combination with other active constituents, including astaxanthin and polymeric hyaluronic acid or sodium hyaluronate (hyaluronan) in an oral dosage form.

## Claims

### Claim at position 1

1-21. (canceled)

### Claim 22

A dietary supplement composition formulated in a therapeutic amount to treat and alleviate symptoms of joint pain, wherein the composition includes a krill oil in combination with astaxanthin and low molecular weight polymers of hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of less than 230 kilodaltons (kDa) in an oral dosage form.

### Claim 23 (depends on 22)

The composition according to claim 22, wherein the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids.

### Claim 24 (depends on 22)

The composition according to claim 22, wherein the krill oil includes at least 10% EPA and 5% DHA, of which not less than 40% are in the form of phospholipids.

### Claim 25 (depends on 22)

The composition according to claim 22, wherein the astaxanthin is derived from Haematococcus pluvialis algae, Pfaffia, krill, or by synthetic routes, in the free diol, monoester or diester form.

### Claim 26 (depends on 22)

The composition according to claim 22, wherein the hyaluronan is micro- or nano-dispersed within the composition.

### Claim 27 (depends on 22)

The composition according to claim 22, wherein the hyaluronic acid is derived from a biofermentation process.

### Claim at position 8

28-34. (canceled)

### Claim 35

A dietary supplement composition formulated in a therapeutic amount to treat and alleviate symptoms of non-disease state joint pain in a patient, wherein the composition includes a krill oil derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids and includes at least 10% EPA and 5% DHA, of which not less than 40% are in the form of phospholipids, and in combination with astaxanthin and low molecular weight hyaluronic acid or sodium hyaluronate (hyaluronan) having a molecular weight of less than 230 kilodaltons (kDa) in an oral dosage form.

### Claim 36 (depends on 35)

The composition according to claim 35, wherein the astaxanthin is derived from Haematococcus pluvialis algae, Pfaffia, krill, or by synthetic routes, in the free diol, monoester or diester form.

### Claim 37 (depends on 35)

The composition according to claim 35, wherein the hyaluronic acid or sodium hyaluronate (hyaluronan) are derived from microbial fermentation or animal tissue.

### Claim 38 (depends on 35)

The composition according to claim 35, wherein the hyaluronan is micro- or nano-dispersed within the composition.
